Xilio Therapeutics Taps Immuno-Oncology Veteran as CMO to Advance Pipeline
Event summary
- Xilio Therapeutics appointed Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer on September 28, 2026.
- Dr. Houvras brings over 20 years of experience in immuno-oncology, including leadership roles at Tubulis and Regeneron.
- He will oversee the advancement of XTX501, a bispecific PD-1/masked IL-2 therapy, and next-generation multi-specific T cell engagers.
- Prior to Xilio, Dr. Houvras led clinical development programs at Tubulis through its acquisition by Gilead Sciences.
The big picture
Xilio's appointment of Dr. Houvras underscores its push to differentiate in the competitive immuno-oncology space through masked therapies. His background in bispecifics and ADCs aligns with Xilio's goal of developing tumor-selective treatments, addressing a critical need for reducing systemic side effects. The move comes as biotech firms increasingly prioritize precision oncology, with Houvras' track record in global clinical development positioning Xilio to compete with larger players like Gilead and Regeneron.
What we're watching
- Pipeline Momentum
- How Dr. Houvras' expertise will accelerate XTX501's clinical progress and next-generation programs.
- Strategic Partnerships
- Whether Xilio can leverage Houvras' industry connections to strengthen collaborations with Gilead and AbbVie.
- Regulatory Pathways
- The pace at which Xilio can navigate regulatory hurdles for its masked immuno-oncology therapies.
Related topics